- Home
- OCSL vs DVAX Comparison
OCSL vs DVAX Comparison
Compare OCSL & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCSL
- DVAX
- Stock Information
- Founded
- OCSL 2007
- DVAX 1996
- Country
- OCSL United States
- DVAX United States
- Employees
- OCSL N/A
- DVAX N/A
- Industry
- OCSL Finance: Consumer Services
- DVAX Biotechnology: Pharmaceutical Preparations
- Sector
- OCSL Finance
- DVAX Health Care
- Exchange
- OCSL Nasdaq
- DVAX Nasdaq
- Market Cap
- OCSL 1.1B
- DVAX 1.2B
- IPO Year
- OCSL 2008
- DVAX 2004
- Fundamental
- Price
- OCSL $13.64
- DVAX $11.21
- Analyst Decision
- OCSL Hold
- DVAX Buy
- Analyst Count
- OCSL 6
- DVAX 4
- Target Price
- OCSL $15.20
- DVAX $26.50
- AVG Volume (30 Days)
- OCSL 793.0K
- DVAX 1.7M
- Earning Date
- OCSL 11-18-2025
- DVAX 11-05-2025
- Dividend Yield
- OCSL 11.69%
- DVAX N/A
- EPS Growth
- OCSL N/A
- DVAX N/A
- EPS
- OCSL 0.55
- DVAX N/A
- Revenue
- OCSL $334,099,000.00
- DVAX $330,514,000.00
- Revenue This Year
- OCSL N/A
- DVAX $23.23
- Revenue Next Year
- OCSL N/A
- DVAX $16.57
- P/E Ratio
- OCSL $25.04
- DVAX N/A
- Revenue Growth
- OCSL N/A
- DVAX 26.73
- 52 Week Low
- OCSL $12.44
- DVAX $9.20
- 52 Week High
- OCSL $16.53
- DVAX $14.63
- Technical
- Relative Strength Index (RSI)
- OCSL 51.35
- DVAX 66.14
- Support Level
- OCSL $13.42
- DVAX $9.92
- Resistance Level
- OCSL $13.82
- DVAX $11.43
- Average True Range (ATR)
- OCSL 0.22
- DVAX 0.35
- MACD
- OCSL -0.04
- DVAX 0.10
- Stochastic Oscillator
- OCSL 24.72
- DVAX 86.42
About OCSL Oaktree Specialty Lending Corporation
Oaktree Specialty Lending Corp is a specialty finance company. The company provides lending services and invests in small and mid-sized companies. The company's investment objective is to maximize its portfolio's total return by generating current income from debt investments, and to a lesser extent, capital appreciation from equity investments. The company provides customized, one-stop credit solutions to companies with limited access to public or syndicated capital markets.
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.